PE20232047A1 - Quinolinas y azaquinolinas como inhibidores de cd38 - Google Patents
Quinolinas y azaquinolinas como inhibidores de cd38Info
- Publication number
- PE20232047A1 PE20232047A1 PE2023002190A PE2023002190A PE20232047A1 PE 20232047 A1 PE20232047 A1 PE 20232047A1 PE 2023002190 A PE2023002190 A PE 2023002190A PE 2023002190 A PE2023002190 A PE 2023002190A PE 20232047 A1 PE20232047 A1 PE 20232047A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compounds
- inhibitors
- alkynyl
- alkenyl
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title abstract 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Referido a compuestos de Formula I, o una sal farmaceuticamente aceptable del mismo, donde: X3 es CR3 o N; X4 es CR4 o N; A es un heteroarilo de 5 miembros que tiene 1, 2 o 3 heteroatomos seleccionados entre N, O, y S, opcionalmente sustituido; L es un conector C1-C4 alquileno; n es 0 o 1; Q es H, C1-C10 alquilo, C2-C10 alquenilo, C2-C10 alquinilo, entre otros; R1 es C1-6 alquilo; R2, R3, y R4 se seleccionan en forma independiente entre si entre H, halo, C1-C6 alquilo, C2-C6 alquenilo, C2-C6 alquinilo, entre otros. Un compuesto seleccionado es 6-(1H-imidazol-1-il)-4-(((1r,4r)-4-(2-metoxietoxi)ciclohexil)amino)-1-metilquinolin-2(1H)-ona. Estos compuestos de quinolinas y azaquinolinas son inhibidores de CD38. Tambien se refiere la sintesis de estos compuestos, una composicion farmaceutica que los comprende y su uso para el tratamiento del cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143245P | 2021-01-29 | 2021-01-29 | |
| PCT/US2022/014221 WO2022165114A1 (en) | 2021-01-29 | 2022-01-28 | Quinolines and azaquinolines as inhibitors of cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20232047A1 true PE20232047A1 (es) | 2023-12-27 |
Family
ID=80446310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002190A PE20232047A1 (es) | 2021-01-29 | 2022-01-28 | Quinolinas y azaquinolinas como inhibidores de cd38 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11952377B2 (es) |
| EP (1) | EP4284511A1 (es) |
| JP (1) | JP2024506814A (es) |
| KR (1) | KR20230141799A (es) |
| CN (1) | CN117580829A (es) |
| AR (1) | AR124718A1 (es) |
| AU (1) | AU2022212035A1 (es) |
| BR (1) | BR112023014898A2 (es) |
| CA (1) | CA3208851A1 (es) |
| CL (1) | CL2023002163A1 (es) |
| CO (1) | CO2023009803A2 (es) |
| CR (1) | CR20230323A (es) |
| DO (1) | DOP2023000142A (es) |
| EC (1) | ECSP23056223A (es) |
| IL (1) | IL304466A (es) |
| PE (1) | PE20232047A1 (es) |
| TW (1) | TW202241418A (es) |
| WO (1) | WO2022165114A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012075080A1 (en) | 2010-12-01 | 2012-06-07 | Glaxosmithkline Llc | Indoles |
| AU2012332297B2 (en) | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| MX367420B (es) * | 2013-03-14 | 2019-08-21 | Convergene Llc | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. |
| EP3227275B1 (en) | 2014-12-03 | 2019-01-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Cd38 inhibitors and methods of treatment |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| AU2020321956A1 (en) | 2019-07-31 | 2022-03-10 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| US20230025807A1 (en) | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| KR20230051425A (ko) | 2020-04-07 | 2023-04-18 | 미토브리지, 인크. | Cd38 억제제 |
-
2022
- 2022-01-28 US US17/586,939 patent/US11952377B2/en active Active
- 2022-01-28 BR BR112023014898A patent/BR112023014898A2/pt unknown
- 2022-01-28 WO PCT/US2022/014221 patent/WO2022165114A1/en active Application Filing
- 2022-01-28 CR CR20230323A patent/CR20230323A/es unknown
- 2022-01-28 CA CA3208851A patent/CA3208851A1/en active Pending
- 2022-01-28 CN CN202280022060.6A patent/CN117580829A/zh active Pending
- 2022-01-28 AR ARP220100173A patent/AR124718A1/es unknown
- 2022-01-28 TW TW111103880A patent/TW202241418A/zh unknown
- 2022-01-28 PE PE2023002190A patent/PE20232047A1/es unknown
- 2022-01-28 AU AU2022212035A patent/AU2022212035A1/en active Pending
- 2022-01-28 JP JP2023544674A patent/JP2024506814A/ja active Pending
- 2022-01-28 KR KR1020237027359A patent/KR20230141799A/ko unknown
- 2022-01-28 EP EP22704226.4A patent/EP4284511A1/en active Pending
-
2023
- 2023-07-13 IL IL304466A patent/IL304466A/en unknown
- 2023-07-24 CL CL2023002163A patent/CL2023002163A1/es unknown
- 2023-07-25 EC ECSENADI202356223A patent/ECSP23056223A/es unknown
- 2023-07-25 DO DO2023000142A patent/DOP2023000142A/es unknown
- 2023-07-25 CO CONC2023/0009803A patent/CO2023009803A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022165114A1 (en) | 2022-08-04 |
| IL304466A (en) | 2023-09-01 |
| CN117580829A (zh) | 2024-02-20 |
| CL2023002163A1 (es) | 2024-01-05 |
| AR124718A1 (es) | 2023-04-26 |
| ECSP23056223A (es) | 2023-11-30 |
| CR20230323A (es) | 2023-10-02 |
| EP4284511A1 (en) | 2023-12-06 |
| JP2024506814A (ja) | 2024-02-15 |
| BR112023014898A2 (pt) | 2023-10-31 |
| CA3208851A1 (en) | 2022-08-04 |
| US11952377B2 (en) | 2024-04-09 |
| TW202241418A (zh) | 2022-11-01 |
| DOP2023000142A (es) | 2023-08-31 |
| US20220242862A1 (en) | 2022-08-04 |
| KR20230141799A (ko) | 2023-10-10 |
| AU2022212035A1 (en) | 2023-08-03 |
| CO2023009803A2 (es) | 2023-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
| EA202192019A1 (ru) | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения | |
| EA202192029A1 (ru) | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| PH12019550083A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PE20050772A1 (es) | Piperidinilcarbonil-pirrolidinas como agonistas de melanocortina | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl |